Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00203307 · ClinicalTrials.gov registry record · NA
A Research Study Examining the Use of Olanzapine for the Prevention of Migraine
A NA study, sponsored by Thomas Jefferson University.
- Terminated
- Registry status
- NA
- Development phase
- 3
- Enrollment target
NCT00203307 is a NA study that was terminated before completion, run by Thomas Jefferson University. The registered enrollment target is 3 participants.
The verdict
NCT00203307, a NA study, was terminated before completion, sponsored by Thomas Jefferson University.
- TERMINATED
- Registry status
- NA
- Development phase
- 3 participants
- Enrollment target
Study Summary
Olanzapine (o-lan-zah-peen) is a medication that has been approved by the Food and Drug Administration (FDA) for the treatment of patients with schizophrenia and/ or bipolar disorder. The trade name for this drug is Zyprexa®. Olanzapine has not been approved by the FDA for the prevention of migraine and is experimental for the purposes of this research study. The Jefferson Headache Center at Thomas Jefferson University has developed this clinical study to evaluate the safety and effectiveness of Olanzapine in preventing migraine headaches.
Interventions
- DRUG Olanzapine during first intervention period and placebo during second intervention period
- DRUG Placebo during first intervention period, then olanzapine during second intervention period
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2004-05 |
| Est. Completion | 2006-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00203307
The ClinicalTrials.gov registry entry for NCT00203307 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Thomas Jefferson University, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Olanzapine during first intervention period and placebo during second intervention period is the first listed.
NCT00203307 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00203307 about?
NCT00203307 is a clinical study titled "A Research Study Examining the Use of Olanzapine for the Prevention of Migraine". Olanzapine (o-lan-zah-peen) is a medication that has been approved by the Food and Drug Administration (FDA) for the treatment of patients with schizophrenia and/ or bipolar disorder. The trade name for this drug is Zyprexa®. Olanzapine has not been approved by the FDA for the prevention of migraine...
What is the current status of trial NCT00203307?
This trial is currently terminated. It is a NA study. The enrollment target is 3 participants. The study started on 2004-05. Estimated completion is 2006-06.
What interventions are being tested in trial NCT00203307?
The interventions under investigation include: Olanzapine during first intervention period and placebo during second intervention period (DRUG), Placebo during first intervention period, then olanzapine during second intervention period (DRUG).
Who is sponsoring clinical trial NCT00203307?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.